Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia

BACKGROUND: Patients with relapsed/refractory (R/R) Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) have a poor prognosis and limited treatment options. METHODS: The efficacy of inotuzumab ozogamicin (InO), a humanized anti‐CD22 monoclonal antibody conjugated to the cytotox...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer
Prif Awduron: Stock, Wendy, Martinelli, Giovanni, Stelljes, Matthias, DeAngelo, Daniel J., Gökbuget, Nicola, Advani, Anjali S., O’Brien, Susan, Liedtke, Michaela, Merchant, Akil A., Cassaday, Ryan D., Wang, Tao, Zhang, Hui, Vandendries, Erik, Jabbour, Elias, Marks, David I., Kantarjian, Hagop M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2020
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7983935/
https://ncbi.nlm.nih.gov/pubmed/33231879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33321
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg